This wiki has undergone a migration to Confluence found Here
<meta name="googlebot" content="noindex">

Difference between revisions of "2017-08-10 Patient Care FHIR Call"

From HL7Wiki
Jump to navigation Jump to search
Line 206: Line 206:
  
 
=== Joint Discussion PC/OO/Pharmacy ===
 
=== Joint Discussion PC/OO/Pharmacy ===
 
Patient Care WGM agenda: [[PC_Sept_2017_WGM]]
 
  
 
Questions raised about BiologicallyDerivedProduct (which can include blood products, tissues, organs) as well as procedures that are dosed (e.g. radiation-therapy & light therapy)  
 
Questions raised about BiologicallyDerivedProduct (which can include blood products, tissues, organs) as well as procedures that are dosed (e.g. radiation-therapy & light therapy)  
Line 226: Line 224:
  
  
 +
=== WGM Planning ===
 +
Patient Care WGM agenda: [[PC_Sept_2017_WGM]]
 +
<br>
 
SOAP / ClinicalImpression
 
SOAP / ClinicalImpression
 
* [http://gforge.hl7.org/gf/project/fhir/tracker/?action=TrackerItemEdit&tracker_item_id=12676 GF#12676] Guidance request for GP SOAP in FHIR (Alexander Henket) -  
 
* [http://gforge.hl7.org/gf/project/fhir/tracker/?action=TrackerItemEdit&tracker_item_id=12676 GF#12676] Guidance request for GP SOAP in FHIR (Alexander Henket) -  

Revision as of 20:36, 10 August 2017



Meeting Information

Patient Care FHIR Resources Conference Call

Location: Conference Call
Phone Number: +1 770-657-9270
Participant Passcode: 943377
WebEx: https://cernermeeting.webex.com/join/michelle.m.miller

Date: 2017-08-10
Time: 5-6:30pm ET
Facilitator Michelle M Miller Note taker(s) Michelle M Miller
Attendee Name Affiliation


Elaine Ayres NIH/Department of Clinical Research Informatics
Dave Carlson VA
Stephen Chu The Australian Digital Health Agency (ADHA)
Evelyn Gallego EMI Advisors LLC
Eric Haas Haas Consulting
Rob Hausam Hausam Consulting LLC
Laura Heermann-Langford Intermountain Healthcare
Emma Jones Allscripts
Russ Leftwich InterSystems
Tony Little Optum 360
Jay Lyle Ockham Information Services LLC, VA
Russell McDonell Telstra Health
Lloyd McKenzie Gevity (HL7 Canada)
Larry McKnight Cerner
Michelle M Miller Cerner
Lisa Nelson Life Over Time Solutions
Viet Nguyen Lockheed Martin, Systems Made Simple
M'Lynda Owens Cognosante
Mike Padula The Children's Hospital of Philadelphia
Craig Parker Intermountain Healthcare
Joe Quinn Optum
Simon Sum Academy of Nutrition and Dietetics
Iona Thraen Dept of Veterans Affairs
Serafina Versaggi Dept of Veterans Affairs
Buitendijk,Hans Cerner
JD Nolen
Kenneth McCaslin Accenture
Lorraine Constable
Patrick Loyd
Riki Merrick
Melva Peters Gevity
John Hatem
Jean Duteau
Scott Robertson
Jose Costa Teixeira
Grahame Grieve
Quorum Requirements Met: yes

Agenda

Agenda Topics

  1. Agenda review
  2. Approve previous meeting minutes 2017-08-03_Patient_Care_FHIR_Call
    • Motion: <moved>/<seconded>
  3. OO/PC/Pharmacy Joint Discussion

Supporting Information

Minutes

Joint Discussion PC/OO/Pharmacy

Questions raised about BiologicallyDerivedProduct (which can include blood products, tissues, organs) as well as procedures that are dosed (e.g. radiation-therapy & light therapy)

  • GF#8458 Is a blood transfusion closer to a medication administration or a procedure, or something else?
  • GF#12993 Please Create a NonMedicationAdministration object or an Administration object
  • GF#12673 How to handle HCT/TP
  • GF#13047 and GF#12966 Add DosageInstructions to Procedure/ProcedureRequest
  • 2017-04-13_Patient_Care_FHIR_Call
    • NMDP (National Marrow Donor Program) and CIBTMR (Center for International Blood and Marrow Transplant Research) would like to participate in helping develop a new resource for transplant material
    • It would include things like bone marrow, cord blood, peripheral blood stem cells - and any new resource could also address solid organs and blood transfusion although not part of the initial use case
    • Align with scope of ISBT128, the purpose of which is: to provide standards and guidance for the coding and labeling of medical products of human origin (MPHO): blood, cellular therapy, tissues, regenerated tissue, milk, fecal microbiota, topical products of human origin, in vivo diagnostic MPHO, and organs for transplant, as well as those plasma derivatives for which ABO is relevant. (we may want to extend the scope to “biological origin” rather than limiting to “human origin”)
  • Per Feb 2016 OO ListServ, proposed boundaries included
    • Device: a manufactured item that is used in the provision of healthcare without being substantially changed through that activity. The device may be a medical or non-medical device
    • Substance: A homogeneous material with a definite composition
    • BiologicallyDerivedProduct: material extracted from a living mammalian organism or that is still living


WGM Planning

Patient Care WGM agenda: PC_Sept_2017_WGM
SOAP / ClinicalImpression

Adjourn

Adjourned at <hh:mm am/pm> <timezone>.

Meeting Outcomes

Actions
Next Meeting/Preliminary Agenda Items
  1. Agenda review
  2. Approve previous meeting minutes 2017-08-03_Patient_Care_FHIR_Call
    • Motion: <moved>/<seconded> Abstain - <#>, Negative - <#>, Approve - <#>
  3. gForge change request

© 2012 Health Level Seven® International. All rights reserved.